Introduction
============

Bailey & Cushing provided the first classification of gliomas developing in the central nervous system (CNS) based on the presumed developmental tree of the CNS. This lineage-oriented classification has long been a central concept of the WHO (World Health Organization) classification of tumors of the CNS, even in the current 4th edition (WHO 2007),^[@B1]^ which outlined the genetic profile of each tumor. Nonetheless, it is now clear that neuroepithelial tumors have the wide potential to differentiate beyond that presumed developmental tree and that the various lineages of differentiation do not necessarily correlate with the biological behavior of the underlying tumor. For example, infiltrating astrocytomas and oligodendrogliomas may demonstrate focal neuronal differentiation^[@B2]^; however, the lesions with neuronal differentiation generally do not display a better prognosis. The correlations between genetics and clinical values are often higher than that observed with histology. Therefore, the lineage-oriented classification of gliomas appears no longer to be rational. The cancer stem cell theory is thus proposed to understand the phenomena regarding glioma biology.^[@B3]^

This review summarizes the basic concept of adult glioma pathology, as well as understanding of major genetic alterations in gliomas and the diagnostic potential of these alterations.

WHO Grading Scheme
==================

The WHO classification of tumors of the CNS includes a grading method that involves a "malignancy scale," i.e., the expected prognosis of each tumor, rather than a histological grading system.^[@B4]^ The main rule in the WHO grading scheme is that each tumor entity and grade is fully matched.^[@B1]^ That means WHO grade is automatically given when the diagnosis is determined and it does not allow different grades in histological tumor type regardless of its genetic profiles. The WHO grade offers a means of predicting the biological behavior of a neoplasm and determining the adjuvant radiation and/or chemotherapy protocol. For each tumor entity, a combination of clinical parameters, such as the age of the patient, performance status, and extent of surgical resection contribute to the overall estimate of the prognosis. Despite these variables, a WHO grade of II is given to patients who typically survive for more than 5 years, while a grade of III is given to those who survive for 2--3 years. The prognosis of patients with WHO grade IV tumors largely depends on the availability of an effective treatment regimen. The majority of glioblastoma patients, particularly the elderly, succumb to the disease within 1 year, while the 5-year survival rate of patients with medulloblastoma treated under standard regimens exceeds 60%.^[@B4]^ The WHO grading system has been successfully applied to a spectrum of diffusely infiltrative astrocytic tumors, although it is not fully applicable to other gliomas, including oligodendrogliomas and ependymomas.

The WHO grading scheme is composed of a four-tiered scale similar to that of the St. Anne/Mayo system, with the major difference being grade l,^[@B5]^ as the WHO classification assigns grade l to circumscribed, benign neoplasms with a possibility of achieving a cure following surgical resection alone,^[@B1]^ whereas the St. Anne/Mayo classification assigns grade l to exceedingly rare diffuse astrocytic tumors without atypia. As currently defined by the WHO, lesions designated as grade II to IV are infiltrative in nature and considered malignant in biology.

Four benchmarks, atypia, mitosis, microvascular proliferation, and necrosis are used to assess tumor grading. Tumors with cytological atypia alone are considered to be of grade II, while those also showing anaplasia and a mitotic activity is considered to be grade III, and lesions additionally demonstrating microvascular proliferation and/or necrosis to be grade IV.^[@B1]^

Atypia is defined as variation in nuclear shape or size accompanying hyperchromasia. Anaplasia is defined as a loss of structural differentiation indicating reversion of the cells to an immature or a less differentiated form. Distinct nuclear atypia with apparent hypercellularity is accepted as a sign of anaplasia. No special recognition is given to their number or morphology of mitosis. Since the finding of a solitary mitosis in an ample specimen does not confer grade III behavior, separating grade II from grade III tumors may be achieved more reliably by determining the pHH3-labeling index.^[@B6],[@B7]^ PHH3 (phosphohistone H3) is a core histone protein that reaches a maximum for chromatin condensation during mitosis. Anti-pHH3 specifically detected the histone H3 only when phosphorylated while the histone H3 is not phosphorylated during apoptosis. Therefore, anti-pHH3 can serve as a useful mitotic marker to separate mitotic figures from apoptotic bodies. Microvascular proliferation (previously called endothelial proliferation; pure proliferation of the endothelium is rare) is defined as the presence of a glomeruloid vasculature consisting of smooth muscle cells/pericytes. Necrosis may be of any type; perinecrotic palisading need not be present. The aforementioned benchmarks make their appearance in a predictable sequence: atypia followed in turn by a mitotic activity with increased cellularity and finally microvascular proliferation and/or necrosis.^[@B1],[@B4]^

Classification of Diffuse Gliomas
=================================

Gliomas comprise three common histologic subtypes: astrocytomas, oligodendrogliomas, and ependymomas, based on the morphological similarities of these lesions to their normal cellular counterparts ([Table 1](#T1){ref-type="table"}).

I.. Astrocytoma
---------------

Astrocytes are multipolar, "star-like" cells of the CNS with an eosinophilic cytoplasm and processes. On immunohistochemistry, glial fibrillary acidic protein (GFAP), a main constituent of glial fibrils, is a hallmark of astrocytic differentiation, but it is obviously not neoplasm-specific and is less expressed in undifferentiated examples. The term "astrocytoma" widely applies to tumors that exhibit astrocytic differentiation, i.e., circumscribed and low-grade astrocytomas as well as infiltrating malignant astrocytomas. Circumscribed astrocytomas correspond to unique astrocytoma variants, including pilocytic astrocytoma, subependymal giant cell astrocytoma, and pleomorphic xanthoastrocytoma ([Table 1](#T1){ref-type="table"}). Infiltrating astrocytomas are divided into three subtypes, i.e., diffuse astrocytoma grade II, anaplastic astrocytoma grade III, and glioblastoma grade IV, the last being the most aggressive infiltrating glioma of the astrocytic lineage. Diffuse and anaplastic astrocytomas have a tendency to progress to higher grades.^[@B8]^ For example, low-grade diffuse astrocytoma transforms into anaplastic astrocytoma of grade III and glioblastomas (GBMs) of grade IV, respectively. Characteristic genetic events in diffuse astrocytoma and anaplastic astrocytoma are *isocitrate dehydrogenases (IDHs) 1/2* mutations that are followed by *TP53* mutations and alpha-thalassemia/mental retardation syndrome X-linked (*ATRX*) mutations^[@B9],[@B10]^ ([Fig. 1](#F1){ref-type="fig"}). Although morphologically indistinguishable, GBMs seem to comprise of several subtypes. Glioblastomas most frequently arise *de novo* ("primary" GBM), while tumors that progress from lower grades are called "secondary" GBM.^[@B8],[@B11]^

Recently, *BRAF* (the B-isoform of the rapidly growing fibrosarcoma oncogene) V600E mutation, which has been widely observed in papillary thyroid carcinoma, colorectal cancer, melanoma, and non-small cell lung cancer was identified in epithelioid GBM at a relatively high frequency of 54%.^[@B12]^ The epithelioid GBM, a rare variant of GBMs, is composed of monotonous, pattern-less sheets of small, round cells with laterally positioned nuclei and eosinophilic cytoplasm that are generally GFAP negative but positive for cytokeratins. In the rhabdoid GBM, another rare variant of GBMs, Kleinschmidt-DeMasters et al. reported focal loss of *INI-1* protein in the rhabdoid areas suggesting secondary mutation of *INI-1*.^[@B13]^ Since *IDH* mutations are absent in the epithelioid as well as rhabdoid GBMs, they may represent distinct variants of pGBM.

II.. Oligodendroglioma
----------------------

The term "oligodendroglioma" was coined by Bailey and Cushing based on the resemblance of these lesions to normal oligodendrocytes. The classic histology of oligodendroglioma includes round nuclei of constant size surrounded by a ring of cytoplasm that stains very feebly with a network of fine capillaries and calcification ([Fig. 2](#F2){ref-type="fig"}). As formalin fixation makes the neoplastic cytoplasm swollen, the cell membrane becomes well defined, exhibiting a honeycomb or "fried egg" appearance.^[@B4]^

Oligodendrogliomas abundantly express the Nkx-2.2 homeodomain protein as well as the oligodendrocyte lineage-specific basic helix-loop-helix (Olig) family of transcription factors, particularly Olig2,^[@B14]^ the most widely expressed transcription factor in the embryonic brain among the Olig family. Olig2 interacts with Nkx-2.2,^[@B15]^ which is responsible for directing ventral neuronal patterning in response to graded Sonic hedgehog signaling in the embryonic neural tube. Nonetheless, since no convincing evidence to support an oligodendroglial origin of oligodendrogliomas, such as the expression of myelin-related proteins or the presence of myelin formation on electron microscopy, has been established, it is thought that oligodendrogliomas arise from unknown progenitor cells in the embryonic neural tube.

The WHO 2007 recognizes two major subgroups, oligodendroglioma and oligoastrocytoma, both of which have an anaplastic counterpart. While classic oligodendroglioma is highly characteristic with respect to morphology, the morphology of oligoastrocytomas is heterogeneous and difficult to distinguish from that of astrocytomas in many instances. Thus, the concept of oligoastrocytomas has long been a target of argument. The lack of specific markers results in considerable disagreement between observers regarding the diagnosis of oligodendrogliomas as a whole. Anaplastic oligodendrogliomas also harbors diagnostic problems since there is no definitive criteria to distinguish grade II lesions from grade III ones. On the other hand, codeletion of the chromosome arms 1p and 19q (1p/19q codeletion), a robust predictive and prognostic marker,^[@B16]^ is highly correlated with a classic histology. Although there are no immunohistochemical surrogate markers for molecular testing for the 1p/19q codeletion, the detection of a specific pattern of immunohistochemistry is highly characteristic. For example, low-grade, codeleted oligodendroglioma is almost always positive for mutated isocitrate dehydrogenases (*IDH*)*1*^R132H^ and totally negative for p53.^[@B11],[@B17]^ Vimentin is generally negative, while GFAP and nestin are often positive for glial fibrillary oligodendrocytes and minigemistocytes. Combined with a classic morphology, the immunohistochemical profile can be used to adequately specify codeleted oligodendroglioma.

Practically, oligodendrogliomas can thus be subdivided into two subgroups, tumors with classic morphology (classic for oligodendroglioma, CFO) ([Fig. 2](#F2){ref-type="fig"}) and those without it (non-classic for oligodendroglioma, NCFO) ([Fig. 3](#F3){ref-type="fig"}). CFO corresponds to oligodendroglioma harboring *IDH1* mutations and 1p/19q codeletion but lacking *TP53* mutation (so called "double-positive" glioma) whereas NCFO to those lacking 1p/19q codeletion. Some of NCFO correspond to the tumors harboring an astrocytoma-like genotype, *IDH1* and *TP53* mutations without 1p/19q codeletion ([Fig. 3](#F3){ref-type="fig"}). The remaining are heterogeneous tumors that may lack all of the known genetic alterations ("triple-negative" gliomas) ([Fig. 1](#F1){ref-type="fig"}).^[@B18]^

GBM with oligodendroglioma component (GBMO) was initially deӿned as anaplastic oligoastrocytoma (AOA) with necrosis since two large studies of malignant gliomas suggested that patients affected by AOA with necrosis had a shorter median overall survival compared to patients affected by AOA without necrosis but had a better median overall survival than that of conventional GBMs.^[@B19],[@B20]^ In WHO 2007, however, GBMO is defined as a subgroup of GBMs, i.e., GBM containing foci that resemble oligodendroglioma. Subsequent studies showed heterogeneous results, one supporting the results of the initial studies and the other denying them. Such confusion was likely caused by the ambiguous definition of GBMO.

Correlation between Histopathology and Genetics in Gliomas
==========================================================

As mentioned partly above, major genetic alterations in gliomas include mutations in *IDH-1/-2*, the *TP53* mutation, 1p/19q codeletion, telomerase reverse transcriptase (*TERT*) mutation, and those involving *BRAF.*^[@B9]^ These genetic alterations roughly correspond, in order, to infiltrating astrocytoma/oligodendroglioma, diffuse astrocytoma, classic oligodendroglioma, and circumscribed astrocytoma, respectively. Primary GBM, on the other hand, mostly develops without *IDH1/2* mutations, although this tumor may occur via the acquisition of a *TERT* promoter mutation, *CDKN2A* mutation or homozygous deletion, *EGFR* amplification and/or *PTEN* mutation.^[@B21]--[@B23]^ Secondary sGBM is characterized by *TP53* mutations, *IDH* mutations, and lack of *EGFR* amplification.^[@B24]^ The Cancer Genome Atlas (TCGA) project, a whole gene expression profiling study on various cancers, identified four robust gene expression-based molecular subtypes of GBMs, i.e., proneural, neural, classical, and mesenchymal subtypes.^[@B25]^ Two of those subtypes, proneural and mesenchymal, are almost identical to those reported in other profiling studies and sit at opposite ends. The proneural GBM, which is common in young adults, corresponds to secondary GBM and is associated with better outcome. The secondary GBM is characterized by *IDH/TP53* mutations, a G-CIMP phenotype, and normal *EGFR-PTEN*-*Notch* signaling. The mesenchymal GBM, which is common in older adults, is associated with worse outcome and is characterized by *EGFR* amplification, *PTEN* loss, *NF1* mutations, and Akt signaling.^[@B22]^ From a diagnostic point of view, using a threshold of 10% p53-positive tumor cells, p53 expression can be used as a surrogate marker for missense *TP 53* mutation but not for non-missense mutations.^[@B26]^ No consistent genetic alterations have been found in ependymomas.^[@B27]^ Childhood gliomas rarely carry the genetic alterations seen in adults, including mutations and 1p/19q codeletion, which suggests that distinct sets of genetic aberrations underlie the clinicopathologic differences between adult and pediatric gliomas. In cases of pediatric glioblastoma and diffuse pontine glioma, genetic alterations in genes with histone-related functions and/or chromatin remodeling genes, including *H3F3A* and *ATRX*, have been identified.^[@B28]^

I.. IDH
-------

*IDH* mutations in 1, and to a lesser extent 2, were first identified in 70--80% of low-grade gliomas and a subset of cases of GBM in 2008.^[@B29]^ In contrast to diffuse gliomas, circumscribed astrocytomas and other neuroepithelial tumors, including ependymomas and neuronal tumors, such as gangliogliomas, express few or no mutations.^[@B30],[@B31]^ Glioblastomas harboring *IDH* mutations are mostly secondary GBM lesions that have arisen via progression from lower-grade tumors. *IDH1^R132H^* is the most common mutation (up to 90%), followed by other, more rare, *IDH1* mutations (0.5--5%).^[@B30]^ An antibody against IDH1R132H protein is commercially available for use in formalin-fixed, paraffin-embedded sections.^[@B32],[@B33]^ *IDH* mutations are also found in approximately 5% of primary GBMs. Since primary GBM is a clinically defined entity and the presence of *IDH1/2* mutations have been shown to be inversely related to or even mutually exclusive of *EGFR* and *PTEN* abnormalities,^[@B23]^ which are hallmarks of primary GBM, *IDH*-mutated GBM lesions may represent genetically "secondary" GBM tumors.

*IDH1/2* mutations are often associated with other genetic alterations that occur frequently in astrocytomas and oligodendrogliomas; for example, *TP53* mutations as well as the mutation of *ATRX* occur together with *IDH1/2* mutations in 60% to 70% of infiltrating astrocytomas,^[@B34]^ whereas 1p/19q codeletion is associated with *IDH1/2* mutations in more than 90% of classic oligodendrogliomas.^[@B35]^ Based on studies of initial and recurrent tumors, *IDH* mutations likely occur in the most upstream stage of development of astrocytomas and oligodendrogliomas.^[@B23],[@B36]^ Moreover, the *IDH* mutation status is stable during the progression of low-grade gliomas to secondary high-grade gliomas.^[@B23]^ Taken together, *IDH* mutations may occur in precursor cells that can give rise to both oligodendrocytes and astrocytes. Following *IDH* mutation, additional mutations may specify tumor development along an astrocytic or oligodendrocytic lineage. These additional genetic events may also play important roles in the progression of low-grade gliomas to high-grade gliomas.

*IDH1* mutations are associated with the methylation of O6-methylguanine-DNA methyl transferase (MGMT). Analyses of DNA promoter alterations in MGMT have revealed hypermethylation at the cytosine phosphate-guanine (CPG) island. This phenotype is termed a glioma-CPG methylator phenotype (GCIMP).^[@B36]^ Among GBMs lacking *IDH* mutations, those with MGMT promoter methylation survive significantly longer than those without after receiving temozolomide.^[@B37]^

II.. 1p/19q
-----------

The characteristic 1p/19q codeletion is identified in 50% to 90% of oligodendrogliomas, particularly those bearing a classic morphology, whereas approximately two-thirds of diffuse astrocytic lesions have a concurrent *TP53* mutation. 1p/19q codeletion and *TP53* mutation are mutually exclusive. The codeletion is caused by an unbalanced whole-arm translocation between chromosomes 19 and 1, with a loss of the chromosome t (1p;19q).^[@B34],[@B38],[@B39]^ Oncogenes presumably located at 1p and 19q constitute major targets in glioma research. For example, whole-genome sequence studies have identified mutations of far upstream element binding protein 1 (*FUBP1*) on chromosome 19q13.2 as well as capicua homolog (*CIC*) on 1p31.1 in 83% and 20% of oligodendrogliomas, respectively. However, the significance and mechanisms of these genes in the tumorigenesis of oligodendrogliomas remain unknown. The 1p/19q codeletion is associated with a prolonged survival time and favorable response to procarbazine, CCNU, vincristine (PCV), and temozolomide chemotherapy or radiotherapy.^[@B16]^

Actually, Figarella-Branger et al.^[@B18]^ analyzed *IDH1* mutation, *TP53* mutation, and 1p/19q codeletion in 88 low-grade gliomas and found that they are divided into four groups; group 1, IDH1^R132H^+/p53--/1p19q--; group 2, IDH1^R132H^+/p53--/1p19q+; group 3, IDH1^R132H^+/p53+/1p19q--; and group 4, triple negative glioma. Group 4 carries the worst prognosis and group 2 the best. Since *TP53* mutation and 1p/19q codeletion are always associated with *IDH* mutations, and since *IDH* mutations pose the lowest hazard ratio followed by that of 1p/19q codeletion, infiltrating gliomas can thus be classified as double positive (*IDH*+/1p19q+), single positive (*IDH* or 1p19q+), double negative (*IDH*--/1p19q--), and triple negative gliomas (*IDH*--/1p19q--/*TP53*--), in the sequence of prognosis ([Fig. 1](#F1){ref-type="fig"}).

III.. TERT
----------

Recently, novel somatic mutations in the promoter region of *TERT* have been identified in malignant melanomas. The two most common mutations are located at C228T and C250T, with identical hot spots also found in gliomas. The highest incidence was identified among most tumors harboring 1p/19q loss and *IDH1/2* mutations (98%), as well as *IDH* wild-type tumors with *EGFR* amplification (92%).^[@B21]^ The former corresponds to classic oligodendroglioma, while the latter corresponds to primary GBM. The frequency of *TERT* mutations is relatively low in diffuse and anaplastic astrocytomas (19% and 25%, respectively).^[@B21]^

IV.. BRAF
---------

BRAF is a member of the Raf kinase family of growth signal transduction protein kinases. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which affects cell division, differentiation, and secretion. In pilocytic astrocytomas, particularly those occurring in children, *BRAF-KIAA1549* fusion caused by the duplication of 7q34 is a characteristic event that discriminates pilocytic astrocytomas from diffuse astrocytomas.^[@B40]^ The *BRAF* exon15 V600E mutation is found in approximately 60% of patients with pleomorphic xanthoastrocytoma (PXA).^[@B41],[@B42]^ The presence of subependymal giant cell astrocytoma (SEGA), a major diagnostic criterion for tuberous sclerosis complex (TSC), results from inhibition of the function of *mTOR* (mammalian target for rapamycin) by a tumor suppressor complex formed by tuberin and hamartin.^[@B43]^ The *mTOR*-signaling pathway is part of the MAP kinase/ERK-signaling pathway. Hamartin is encoded by *TSC1* at chromosome 9q34, while tuberin is encoded by *TSC2* located on chromosome 16p. Since rapamycin inhibits the *mTOR* pathway, rapamycin and other *mTOR* inhibitors are often applied to treat TSC.

Conclusion
==========

There is accumulating evidence that tumors with a similar histology share common genetic abnormalities that are clinically significant with respect to the response to treatment and prognosis. In such cases, it is rational that the future classification of gliomas be based on genotype rather than phenotype. For example, oligodendrogliomas with a classic histology are highly correlated with the IDH mutation and 1p/19q codeletion, while those without a classic histology exhibit both heterogeneous histology and genotypes. The latter tumors may contain several subtypes of undefined diffuse gliomas; thus, the pathological diagnosis favors diffuse glioma, NOS (not otherwise specified). In such examples, profiling major genes and/or chromosomes helps clinicians to determine the treatment strategy.

Nonetheless, molecular classification of gliomas has several issues that must be resolved. Obviously, the genetic features of each tumor are not sufficiently understood in order to draw a complete map of gliomas. In addition, genetic testing is not available worldwide, particularly in Asian and African countries. Historical data, which usually lack genetic profiles, cannot be used for direct comparisons with the new classification. Furthermore, many genetic testing parameters are not internationally standardized. For example, several different techniques are used for methylation assays of MGMT, including methylation-specific PCR and pyrosequencing. The establishment of surrogate markers for genetic testing using immunohistochemistry of formalin-fixed, paraffin-embedded sections in developing countries is highly warranted. The next classification scheme should be defined in clinically relevant terms based on markers that define both phenotypes and the response to various therapeutic agents.
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![A model for molecular classification of diffuse gliomas in adults. Alterations in *IDH* lead the *TP53-ATRX-*mutation pathway or the 1p/19q-codeletion-*CIC/FUBP1*-mutation pathway. Pathologically, the former corresponds to diffuse astrocytoma whereas the latter to classic oligodendroglioma. Non-classic oligodendrogliomas and oligoastrocytomas typically lack *IDH* mutation or other genetic signatures. Primary glioblastoma does not have either genetic signature and is likely underlaid by multiple molecular pathways. *ATRX*: alpha-thalassemia/mental retardation syndrome X-linked, *CIC*: capicua homolog, codel: codeletion, *FUBP1*: far upstream element binding protein 1, *IDH*: isocitrate dehydrogenase, mt: mutation, OLG: oligodendroglioma, wt: wild type.](nmc-55-28-g1){#F1}

![Histology of classic oligodendroglioma with double-positive genetic signature. A: Immunohisto-chemistry with isocitrate dehydrogenase *(IDH)1*^R132H^ mutation specific antibody is diffusely positive in tumor cells. B: Fluorescence *in situ* hybridization (FISH) using probes (*orange*) against 1p36 (*left*) and 19q13 (*right*). The cell in each image shows the one orange, two green (control) signal pattern indicative of the 1p36 and 19q13 deletion, respectively. C: Immunohistochemistry with p53 is completely negative. D: Representative hematoxylin and eosin (H&E) staining section of classic oligodendroglioma showing round nuclei of constant size surrounded by halos exhibit a honeycomb or "fried egg" appearance. E: The recurrent tumor 6 years after the initial resection shows essentially identical histology with the original tumor (H&E staining).](nmc-55-28-g2){#F2}

![Histology of non-classic oligodendroglioma with single-positive genetic signature. A: Immunohistochemistry with isocitrate dehydrogenase *(IDH)1*^R132H^ mutation specific antibody is diffusely positive in tumor cells. B: Fluorescence in situ hybridization (FISH) study showing multiple signals of both 1p36 and 19q13 indicative of polysomy. C: Immunohistochemistry with p53 shows abundant positive cells. D: Representative H&E staining section of non-classic oligoastrocytoma. The oligodendroglial component shows round but irregular nuclei. E: The recurrent tumor 2 years after the initial resection shows marked atypia and pleomorphism corresponding to anaplastic oligoastrocytoma (H&E staining).](nmc-55-28-g3){#F3}

###### 

Framework of gliomas

                  WHO grade     Astrocytomas             Oligodendrogliomas            Ependymomas                                            
  --------------- ------------- ------------------------ ----------------------------- ------------------------------ ----------------------- ---------------
  Circumscribed   I                                      Pilocytic astrocytoma                                                                Subependymoma
                  PXA                                                                  Myxopapillary ependymoma                               
                  SEGA                                                                                                                        
  Diffuse         II                                     Diffuse astrocytoma           NCFO                           CFO                     Ependymoma
                                Oligoastrocytoma         Oligodendroglioma                                                                    
  III                           Anaplastic astrocytoma   Anaplastic oligoastrocytoma   Anaplastic oligodendroglioma   Anaplastic ependymoma   
  IV              Primary GBM   Secondary GBM            GBMO                                                                                 

CFO: classic for oligodendroglioma, GBM: glioblastoma, GBMO: glioblastoma with oligodendroglioma component, NCFO: non-classic for oligodendroglioma, PXA: pleomorphic xanthoastrocytoma, SEGA: subependymal giant cell astrocytoma, WHO: World Health Organization.
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